Morgan Stanley analyst David Lewis maintained a Buy rating on Alcon Inc (ALC) on May 31 and set a price target of $65. The company’s shares closed yesterday at $58.95.
According to TipRanks.com, Lewis is a 4-star analyst with an average return of 7.4% and a 61.5% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Shockwave Medical Inc, TransMedics Group Inc, and Edwards Lifesciences.
Alcon Inc has an analyst consensus of Moderate Buy, with a price target consensus of $61.38, a 4.1% upside from current levels. In a report issued on May 17, Credit Suisse also reiterated a Buy rating on the stock with a $68 price target.
See today’s analyst top recommended stocks >>
Based on Alcon Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.79 billion and GAAP net loss of $73 million. In comparison, last year the company earned revenue of $1.76 billion and had a net profit of $329 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through Surgical and Vision Care segments.
